CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
GW815SF Salmeterol/Fluticasone propionate(HFA MDI)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00449046
NCT00449046Phase 3Completed
CompareCT.gov

Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

GlaxoSmithKline·interventional·Posted Mar 19, 2007·Updated May 6, 2015

In Brief

A Phase 3 clinical trial evaluating GW815SF Salmeterol/Fluticasone propionate(HFA MDI) for Bronchial Asthma. Completed, enrolled 40 participants across 3 sites.

Detailed Summary

This study evaluates the long-term (24-week) safety and efficacy of GW815SF Salmeterol/fluticasone propionate(HFA MDI) 50/100mcg(administered as 2 inhalations of 25/50mcg) bid in pediatric patients with bronchial asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchial Asthma
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 19, 2007
Enrollment StartMar 1, 2007
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.3 years ago

Interventions

GW815SF Salmeterol/Fluticasone propionate(HFA MDI)drug